Immunocore Holdings plc

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Immunocore dosed the first patient in the first-in-human Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate, for HLA-A*02:01-positive patients with type 1 diabetes. IMC-S118AI is a bispecific designed to bind HLA-A*02:01 on beta cells and use PD-1 agonism to turn off autoreactive T cells, aiming to preserve insulin production. The dose escalation trial will assess safety, pharmacokinetics and clinical activity. Supporting preclinical data in human pancreas tissue slices, produced with the University of Florida, was recently published in Science Advances. The milestone extends Immunocore's TCR bispecific platform beyond oncology and infectious disease into a third therapeutic area.

•17d ago

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore has achieved target enrollment of 540 patients in TEBE-AM (NCT05549297), its registrational Phase 3 trial of KIMMTRAK (tebentafusp) in previously treated advanced melanoma. The trial randomizes HLA-A*02:01-positive patients whose disease progressed after prior therapy to tebentafusp monotherapy, tebentafusp plus pembrolizumab, or investigator's choice, with overall survival as the primary endpoint. Topline overall survival data are expected as early as the end of 2026; the company sizes the post-PD1 previously treated opportunity at up to 4,000 patients in the United States and Europe.

•1mo ago

Immunocore reports second quarter financial results and provides a business update

Immunocore reported Q2 2026 revenue of $115.9 million from KIMMTRAK, an 18% increase year-over-year, with the company swinging to a net profit of $0.02 per share compared to a $0.20 loss in the prior year. Enrollment in the pivotal Phase 3 TEBE-AM trial is nearing its target of 540 patients, with topline data potentially available by the end of 2026. Five-year overall survival data presented at AACR showed KIMMTRAK doubled the likelihood of survival at five years for patients with metastatic uveal melanoma, reinforcing its standard-of-care status.

•2mo ago

Immunocore reports first quarter financial results and provides a business update

Immunocore reported Q1 2026 net product sales of $106.7 million, up 13.6% year-over-year, driven by volume growth in the U.S. and Europe. Net income more than doubled to $13.0 million, or $0.25 per diluted share, compared to the prior year. Landmark five-year overall survival data presented at AACR showed KIMMTRAK doubled the likelihood of survival at five years compared to control, with a median OS of 21.6 months. The company ended the quarter with $845 million in cash, cash equivalents, and marketable securities. Enrollment in the TEBE-AM Phase 3 trial for second-line cutaneous melanoma is expected to complete in the first half of 2026.

•5mo ago